Table 1.
Age and comorbidity distributions in PCa patients with ADT group and non-ADT group.
| ADT group N = 7903 (70.8%) |
non-ADT group N = 3255 (29.2%) | P-value | |||
|---|---|---|---|---|---|
| Mean age, yr (SD) | 73.2 | (8.31) | 70.7 | (9.84) | <0.0001 |
| Urbanization, n (%) | <0.0001 | ||||
| 1 (highest) | 2259 | (28.6) | 1060 | (32.6) | |
| 2 | 2184 | (27.6) | 871 | (26.8) | |
| 3 | 1151 | (14.6) | 509 | (15.6) | |
| 4 | 1305 | (16.5) | 445 | (13.7) | |
| 5 (lowest) | 1004 | (12.7) | 370 | (11.4) | |
| Comorbidity, n (%) | |||||
| COPD | 2234 | 28.3 | 882 | 27.1 | 0.21 |
| Other cancers | 450 | 5.69 | 220 | 6.76 | 0.03 |
| Heart failure | 266 | 3.37 | 97 | 2.98 | 0.30 |
| Hypertension | 3951 | 50.0 | 1554 | 47.7 | 0.03 |
| Nephrotic syndrome | 1254 | 15.9 | 516 | 15.9 | 0.98 |
| Stroke | 865 | 11.0 | 351 | 10.8 | 0.80 |
| Lower leg fracture or surgery | 379 | 4.80 | 144 | 4.42 | 0.40 |
| Certain medications, n (%) | 32 | 0.40 | 20 | 0.61 | 0.14 |
| Received chemotherapy | 1243 | 15.7 | 259 | 7.96 | <0.0001 |
| Received prostatectomy | 922 | 11.7 | 1319 | 40.5 | <0.0001 |
| Received radiotherapy | 3439 | 43.5 | 859 | 26.4 | <0.0001 |
| ADT, n (%) | |||||
| Surgical castration | 223 | (2.82) | |||
| Anti-androgen | 3472 | (43.9) | |||
| Chemical castration | |||||
| GnRH agonist alone | 1159 | (14.7) | |||
| CAB | 3049 | (38.6) | |||
Values expressed as n (%).
Certain medications include tamoxifen, thalidomide and erythropoietin.
CAB: combined androgen blockade.